MedPageToday -- Daily aspirin use appeared to lower the risk of death from cancer in randomized trial participants, a meta-analysis found. Cancer death rates were 21% lower in study participants assigned to aspirin after five years (95% CI 8% to 32%), and the reduction persisted among those followed for 20 years, according to pooled data on more than 25,000 individuals in eight randomized studies.
